Log In Sign up
The largest database of trusted experimental protocols

Plx8394

Manufactured by MedChemExpress
Visit Supplier

PLX8394 is a selective and potent inhibitor of BRAF(V600E). It functions by binding to and blocking the activity of the BRAF(V600E) protein, which is a common mutation found in various types of cancer.

Automatically generated - may contain errors

Lab products found in correlation

Vemurafenib, by Selleck Chemicals (2 mentions) Plx4032, by MedChemExpress (2 mentions) Lgx818, by MedChemExpress (2 mentions) Gsk2118436a, by Selleck Chemicals (2 mentions) Dabrafenib, by Selleck Chemicals (1 mentions) Etoposide, by Selleck Chemicals (1 mentions) Shp099, by Selleck Chemicals (1 mentions) Rapamycin, by Selleck Chemicals (1 mentions) Trametinib, by Selleck Chemicals (1 mentions) L kynurenine, by Merck Group (1 mentions) Benzo a pyrene, by Merck Group (1 mentions) Resveratrol rsv, by Selleck Chemicals (1 mentions) Stemregenin 1 sr1, by Selleck Chemicals (1 mentions) Ch 223191, by Selleck Chemicals (1 mentions) Ly3009120, by Selleck Chemicals (1 mentions) Az628, by Selleck Chemicals (1 mentions) Tak 632, by Selleck Chemicals (1 mentions) Gdc 0879, by Selleck Chemicals (1 mentions) Azd6244, by Selleck Chemicals (1 mentions) E 100, by Alomone (1 mentions)

4 protocols using plx8394

1

Combination Therapy Evaluation for BRAF-Mutant Cancers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Drugs used in this study are: dabrafenib (Selleckchem, #S2807), trametinib (Selleckchem, #2673), SHP099 (Selleckchem, #S8278), vemurafenib (Selleckchem, #S1267), PLX8394 (MedChemExpress, HY-18972), rapamycin (Selleckchem, #S1039) and etoposide (Selleckchem, #S1225).
Yang C., Tian C., Hoffman T.E., Jacobsen N.K, & Spencer S.L. (2021). Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. Nature Communications, 12, 1747.
+ Open protocol
+ Expand
2

Comparative Analysis of AhR Ligands

Check if the same lab product or an alternative is used in the 5 most similar protocols
The AhR ligands were obtained from: 2,3,7,8-TCDD (TCDD) (Sigma Aldrich, 48599), FICZ (Sigma Aldrich, SML1489), Vemurafenib (Vem, PLX4032) (Selleckchem, RG7204), Dabrafenib (Dab) (Santa Cruz Biotechnology, SC364477), PLX7904 (MedChem Express, HY-18997), PLX8394 (MedChem Express, HY-18972), CH-223191 (Selleckchem, S7711), L-Kynurenine (Sigma Aldrich, K8625), Resveratrol (RSV) (Selleckchem, S1396), StemRegenin 1 (SR1) (Selleckchem, S2858), and Benzo(a)pyrene (B(a)P) (Sigma Aldrich, B1760).
Corre S., Tardif N., Mouchet N., Leclair H.M., Boussemart L., Gautron A., Bachelot L., Perrot A., Soshilov A., Rogiers A., Rambow F., Dumontet E., Tarte K., Bessede A., Guillemin G.J., Marine J.C., Denison M.S., Gilot D, & Galibert M.D. (2018). Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature Communications, 9, 4775.
+ Open protocol
+ Expand
3

Comparative Analysis of BRAF and MEK Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
BRAFi used are as follows: PLX4032 (vemurafenib; MedChemExpress, #HY-12057), LGX818 (encorafenib; MedChemExpress, #HY-15605), GSK2118436A (dabrafenib; Selleckchem, #S2807), PLX8394 (MedChemExpress, #HY-18972), AZ628 (Selleckchem, #S2746), GDC0879 (Selleckchem, #S1104), LY3009120 (Selleckchem, #S7842), and TAK632 (Selleckchem, #S7291). MEKi used are as follows: AZD6244 (selumetinib; Selleckchem, #S1008), BAY86-9766 (refametinib; MedChemExpress, #HY-102156), and benzyl-coelenterazine (NanoLight, #301).
Röck R., Mayrhofer J.E., Torres-Quesada O., Enzler F., Raffeiner A., Raffeiner P., Feichtner A., Huber R.G., Koide S., Taylor S.S., Troppmair J, & Stefan E. (2019). BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. Science Advances, 5(8), eaav8463.
+ Open protocol
+ Expand
4

Evaluating BRAF inhibitor combinations

Check if the same lab product or an alternative is used in the 5 most similar protocols
The reagents used included PLX4032 (vemurafenib; MedChemExpress, HY-12057), LGX818 (encorafenib; MedChemExpress, HY-15605), GSK2118436A (dabrafenib; Selleckchem, S2807), PLX8394 (MedChemExpress, HY-18972), Benzyl-coelenterazine (Nanolight, 301), and human EGF (Alomone Labs, E-100).
Mayrhofer J.E., Enzler F., Feichtner A., Röck R., Fleischmann J., Raffeiner A., Tschaikner P., Ogris E., Huber R.G., Hartl M., Schneider R., Troppmair J., Torres-Quesada O, & Stefan E. (2020). Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Proceedings of the National Academy of Sciences of the United States of America, 117(49), 31105-31113.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!